Recent news on Sensipar

NPS Reports First Quarter 2007 Financial Results and Progress in ...  -  May 9, 2007
CNW Telbec (Communiqués de presse),NPS now believes that higher royalty revenue from Amgen could enable the company to repay its Sensipar(R) secured debt obligations in 2011 or earlier and

Amgen: Still a Bargain Despite Recent Selloff  -  May 14, 2007
Seeking Alpha,...interferes with signals that stimulate growth and survival of the cancer cell; and Sensipar for treating chronic kidney disease patients on dialysis.

CBI and PharmaVoice Announce Recipients of the 2nd Annual ...  -  26 Apr 2007
PR-Inside.com (Pressemitteilung),Amgen and Walgreens received the award for Best Branded Adherence Program for the Persistency Program for Sensipar(R). Annual Forum on Patient Compliance,

Amgen's First Quarter 2007 Revenue Increased 15 Percent to $3.7 ...  -  Apr 23, 2007
Genetic Engineering News (press release),Worldwide sales of Sensipar(R) (cinacalcet HCl) increased 72 percent to $105 million in the first quarter of 2007 versus $61 million during the first

Amgen posts strong results after Aranesp relief  -  Apr 24, 2007
BiopharmaReporter.com,Revenues for Sensipar (cinacalcet) - a treatment for hyperparathyroidism in dialysis patients - rose 72 per cent to $105m, while colorectal cancer therapy

American Kidney Fund launches Part D grant program  -  Apr 3, 2007
Renal Business Today,The program covers bone disease medications, including Fosrenol, Hecterol, Phoslo, Renagel, Sensipar and Zemplar. Burton added that the AKF hopes to add

American Kidney Fund Launches Medicare Part D Grant Program for ...  -  Apr 3, 2007
PR Web (press release),This program covers common bone disease medications, including Fosrenol®, Hectorol®, Phoslo®, Renagel®, Sensipar® and Zemplar®.

NPS Pharmaceuticals Reports 2006 Results and Progress, Announces ...  -  Mar 14, 2007
Earthtimes.orgThis includes two approved products, Sensipar and Preotact, and several promising drug candidates being developed in partnership with some of the world's

Amgen's Trial Of Vectibix Falls Short; ImClone Shares Benefit  -  Mar 25, 2007
BioWorld Online,In January, it told investors it would not file for an expanded indication of Sensipar (cinacalcet HCl) in secondary hypertension after Phase III data

Nephrologists Report Practice Pattern Shifts in the Management of ...  -  Feb 1, 2007
PharmaLive.com (press release),In the management of secondary hyperparathyroidism, nephrologists report that approximately 25% of their ESRD patients are now taking Sensipar,

Aranesp Data Eclipse Amgen's Fourth-Quarter Revenue Growth  -  Jan 26, 2007
BioWorld Online,On another sour note, the company is not filing for an expanded indication of Sensipar (cinacalcet HCl) in secondary hyperparathyroidism in patients with

Calcium must be kept in balance  -  Dec 22, 2006
Fort Wayne News Sentinel,One such drug is cinacalcet (Sensipar). Calcimimetics are FDA-approved to treat hyperparathyroidism only in dialysis patients and in patients with

Calcium must be kept in balance  -  Dec 22, 2006
Fort Wayne News Sentinel,One such drug is cinacalcet (Sensipar). Calcimimetics are FDA-approved to treat hyperparathyroidism only in dialysis patients and in patients with

NPS Pharmaceuticals Reports Third Quarter and Nine Month Results  09 Nov 2006
NMDA receptor. NPS recognized increased royalty revenue from sales of Sensipar(R)/Mimpara(R) (cinacalcet HCl) by Amgen. Cinacalcet ... -Drug Newswire (press release), Market Strategies' Study on Nephrologists Names Amgen as Most ...  Oct 24, 2006
In addition to Aranesp and Epogen, Sensipar adds to this highly valued product portfolio," stated Levin. Relatedly, Cera, a new ... -PR Newswire (press release), NPS Pharmaceuticals Reports Second Quarter and Six Month Operating ...  Aug 3, 2006
In the second quarter of 2006 NPS recognized increased royalty revenue from sales of Sensipar(R)/Mimpara(R) (cinacalcet HCl) by Amgen, celebrated the European ... -MSN Money

NPS Pharmaceuticals Reports Second Quarter and Six Month Operating ...  Aug 3, 2006
Business and Pipeline Update In the second quarter of 2006 NPS recognized increased royalty revenue from sales of Sensipar(R)/Mimpara(R) (cinacalcet HCl) by ... -CNW Telbec (Communiqués de presse)



NPS Elects N. Anthony Coles, MD Chief Executive Officer  May 12, 2006
...its gratitude to Hunter Jackson, the company's co-founder, for his 20 years of leadership and for shepherding two important new medicines, Sensipar(R) and ... - Boursorama

ConjuChem Announces New Executive Vice President, Research and ...  May 11, 2006
Ulich served in a pivotal leadership role for the regulatory filings of such highly successful drugs as Aranesp, Neulasta, Kepivance, Sensipar, and Denosumab. ... - Canada NewsWire

Amgen's First Quarter 2006 Adjusted Earnings Per Share, Excluding ...  Apr 18, 2006
Worldwide sales of Sensipar(R) (cinacalcet HCl) increased 126 percent to $61 million in the first quarter of 2006 versus $27 million during the first quarter ... - Genetic Engineering News

Genzyme's First-Quarter Sales Below Expectations  Apr 19, 2006
This was primarily due to lower than expected Enbrel and Neulasta sales; however, product sales across the board, with the exception of Sensipar, were slightly ... - BioWorld Online (subscription)

Mixed reaction on Amgen spike  Apr 20, 2006
...$896 million. Enbrel sales rose 11 percent to $658 million and global sales of Sensipar jumped 126 percent to $61 million. Ed Nash ... - Monsters and Critics.com





New Phase 2 Data Suggest Treatment of Anemia with Aranesp(R) ...  Mar 13, 2006
...dialysis and will initiate a trial that will study the effect of treating the CKD complication, secondary hyperparathyroidism, with Sensipar(R)/Mimpara(R ... - Genetic Engineering News

New Phase 2 Data Suggest Treatment of Anemia with Aranesp(R) ...  Mar 13, 2006
...requiring dialysis and will initiate a trial that willstudy the effect of treating the CKD complication, secondaryhyperparathyroidism, with Sensipar(R)/Mimpara ... - Finanzen.net

Amgen's Phase 3 RED-HF™ Trial Will Evaluate The Clinical Effect ...  Mar 14, 2006
...and will initiate a trial that will study the effect of treating the CKD complication, secondary hyperparathyroidism, with Sensipar®/Mimpara® (cinacalcet HCl ... - Medical News Today



NPS Pharmaceuticals Reports Fourth Quarter and Year-End Operating ...  Feb 16, 2006
Sensipar(R) and Kineret(R) are trademarks owned by Amgen. Restasis(R) is a trademark owned by Allergan. For further information: Brandi Simpson, Sr. ... - CNW Telbec (Communiqués de presse),

Q1 2004 Amgen Earnings Conference Call - Research and Markets ...  Feb 3, 2006
In 1Q04, AMGN announced that the FDA approved first small molecule therapeutic, Sensipar, for secondary hyperparathyroidism in dialysis patients. ... - Business Wire

Amgen's Fourth Quarter 2005 Adjusted Earnings Per Share Increased ...  Jan 26, 2006
104 75 388 264 NEUPOGEN(R) - International 95 105 411 397 Enbrel(R) - US 645 545 2,470 1,827 Enbrel(R) - International 29 22 103 73 Sensipar(R) - US 37 18 122 ... - Business Wire

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional